RBC Bioscience Corporation (6848) Stock Statistics & Valuation Metrics
Total Valuation
RBC Bioscience Corporation has a market cap or net worth of TWD 294.03M. The enterprise value is ―.
- Market Cap
- TWD 294.03M
- Enterprise Value
- ―
Share Statistics
RBC Bioscience Corporation has 14,273,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 14,273,160
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
RBC Bioscience Corporation’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 4.18%.
- Return on Equity (ROE)
- 0.09
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 4.18%
- Return on Capital Employed (ROCE)
- 0.06
- Revenue Per Employee
- 4.39M
- Profits Per Employee
- 470.86K
- Employee Count
- 50
- Asset Turnover
- 0.30
- Inventory Turnover
- 2.68
Valuation Ratios
The current PE Ratio of RBC Bioscience Corporation is 13.92. RBC Bioscience Corporation’s PEG ratio is -7.01.
- PE Ratio
- 13.92
- PS Ratio
- 1.33
- PB Ratio
- 1.13
- Price to FCF
- 7.01
- Price to Operating Cash Flow
- 7.10
- PEG Ratio
- -7.01
Income Statement
In the last 12 months, RBC Bioscience Corporation had revenue of 219.71M and earned 23.54M in profits. Earnings per share was 1.65.
- Revenue
- 219.71M
- Gross Profit
- 92.59M
- Operating Income
- 35.03M
- Pretax Income
- 29.80M
- Net Income
- 23.54M
- EBITDA
- 51.12M
- Earnings Per Share (EPS)
- 1.65
Cash Flow
In the last 12 months, operating cash flow was 41.40M and capital expenditures 543,000, giving a free cash flow of 41.95M billion.
- Operating Cash Flow
- 41.40M
- Free Cash Flow
- 41.95M
- Free Cash Flow per Share
- 2.94
Dividends & Yields
RBC Bioscience Corporation pays an annual dividend of ―, resulting in a dividend yield of 22.98%
- Dividend Per Share
- ―
- Dividend Yield
- 22.98%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 14.27%
- Earnings Yield
- 7.16%
Stock Price Statistics
- Beta
- 0.38
- 52-Week Price Change
- 16.06%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 42.47
- Average Volume (3m)
- 46.10K
Financial Position
RBC Bioscience Corporation as a current ratio of 1.25, with Debt / Equity ratio of 145.67%
- Current Ratio
- 1.25
- Quick Ratio
- 0.76
- Debt to Market Cap
- 1.62
- Net Debt to EBITDA
- 6.94
- Interest Coverage Ratio
- 3.61
Taxes
In the past 12 months, RBC Bioscience Corporation has paid 6.25M in taxes.
- Income Tax
- 6.25M
- Effective Tax Rate
- 0.21
Enterprise Valuation
RBC Bioscience Corporation EV to EBITDA ratio is 14.89, with an EV/FCF ratio of 15.25.
- EV to Sales
- 2.90
- EV to EBITDA
- 14.89
- EV to Free Cash Flow
- 15.25
- EV to Operating Cash Flow
- 15.45
Balance Sheet
RBC Bioscience Corporation has TWD 43.18M in cash and marketable securities with TWD 388.85M in debt, giving a net cash position of -TWD 345.67M billion.
- Cash & Marketable Securities
- TWD 43.18M
- Total Debt
- TWD 388.85M
- Net Cash
- -TWD 345.67M
- Net Cash Per Share
- -TWD 24.22
- Tangible Book Value Per Share
- TWD 17.12
Margins
Gross margin is 41.85%, with operating margin of 12.13%, and net profit margin of 9.55%.
- Gross Margin
- 41.85%
- Operating Margin
- 12.13%
- Pretax Margin
- 11.99%
- Net Profit Margin
- 9.55%
- EBITDA Margin
- 19.48%
- EBIT Margin
- 12.13%
Analyst Forecast
The average price target for RBC Bioscience Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 9.29%
- EPS Growth Forecast
- 7.50%
